Suppr超能文献

阿加曲班作为体外膜肺氧合期间肝素诱导的血小板减少症的替代抗凝剂。

Argatroban for an alternative anticoagulant in HIT during ECMO.

作者信息

Rougé Alain, Pelen Felix, Durand Michel, Schwebel Carole

机构信息

Service de Réanimation Médicale, CHU des Alpes, CS 10217, 38043 Grenoble Cedex 9, France.

Université de Grenoble Alpes France, Grenoble, France.

出版信息

J Intensive Care. 2017 Jun 28;5:39. doi: 10.1186/s40560-017-0235-y. eCollection 2017.

Abstract

BACKGROUND

Extracorporeal membrane oxygenation (ECMO) have become more frequently used in daily ICU practice, heparin-induced thrombocytopenia (HIT) is a rare but life-threatening complication while on extracorporeal membrane oxygenation (ECMO). HIT confirmation directly impacts on anticoagulant strategy requiring no delay unfractionated heparin discontinuation to be replaced by alternative systemic anticoagulant treatment.

CASE PRESENTATION

We report two clinical cases of HIT occurring during ECMO in various settings with subsequent recovery with argatroban and provide literature review to help physicians treat HIT during ECMO in clinical daily practice.

CONCLUSIONS

HIT during ECMO is uncommon, and despite the absence of recommendation, argatroban seems to be an appropriate and safe therapeutic option. Finally, there are not enough arguments favouring routine circuit change in the event of HIT during ECMO.

摘要

背景

在重症监护病房(ICU)的日常实践中,体外膜肺氧合(ECMO)的使用越来越频繁,肝素诱导的血小板减少症(HIT)是体外膜肺氧合(ECMO)期间一种罕见但危及生命的并发症。HIT的确诊直接影响抗凝策略,需要立即停用普通肝素,代之以其他全身抗凝治疗。

病例报告

我们报告了两例在不同情况下ECMO期间发生HIT的临床病例,随后使用阿加曲班康复,并提供文献综述以帮助医生在临床日常实践中治疗ECMO期间的HIT。

结论

ECMO期间发生HIT并不常见,尽管缺乏相关推荐,但阿加曲班似乎是一种合适且安全的治疗选择。最后,在ECMO期间发生HIT时,没有足够的理由支持常规更换体外循环回路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05bb/5490178/18b87a07c869/40560_2017_235_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验